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ABSTRACT Anaerobic and aerobic bacteria were quantitated in respiratory samples across three cystic
fibrosis (CF) centres using extended culture methods. Subjects aged 1–69 years who were clinically stable
provided sputum (n=200) or bronchoalveolar lavage (n=55). 18 anaerobic and 39 aerobic genera were cultured
from 59% and 95% of samples, respectively; 16 out of 57 genera had a ⩾5% prevalence across centres.
Analyses of microbial communities using co-occurrence networks in sputum samples showed groupings
of oral, including anaerobic, bacteria, whereas typical CF pathogens formed distinct entities. Pseudomonas
was associated with worse nutrition and F508del genotype, whereas anaerobe prevalence was positively
associated with pancreatic sufficiency, better nutrition and better lung function. A higher total anaerobe/
total aerobe CFU ratio was associated with pancreatic sufficiency and better nutrition. Subjects grouped by
factor analysis who had relative dominance of anaerobes over aerobes had milder disease compared with a
Pseudomonas-dominated group with similar proportions of subjects that were homozygous for F508del.
In summary, anaerobic bacteria occurred at an early age. In sputum-producing subjects anaerobic
bacteria were associated with milder disease, suggesting that targeted eradication of anaerobes may not be
warranted in sputum-producing CF subjects.
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Introduction
Antibiotic therapies for cystic fibrosis (CF) respiratory infections are targeted at specific bacteria, typically
Staphylococcus aureus, Pseudomonas aeruginosa and other Gram-negative species. However, both
culture-dependent and culture-independent molecular methods have redefined CF respiratory infections as
polymicrobial, with a diverse lower airways bacterial community [1]. Anaerobic conditions have been
described in CF lower airways [2, 3]. Importantly, obligate and facultative anaerobic bacteria, typically
associated with the oral cavity, have been cultured in abundance from CF respiratory samples [4, 5].
Indeed, extended anaerobic culture methods identified anaerobic bacteria in high numbers in >60% of CF
sputum samples from adults [6].
The role of anaerobic bacteria in CF lower airways disease is not clearly understood. Studies have
identified anaerobic bacteria from direct lung samples, suggesting their presence does not simply reflect
salivary contamination during sampling [7]. In vitro studies have demonstrated that anaerobes release
virulence factors, including proteases and pro-inflammatory short-chain fatty acids [8, 9], suggesting that
anaerobes may be pathogenic in the CF lung. In contrast, in vivo molecular studies indicate that greater
anaerobe diversity is associated with milder disease [10, 11]. Molecular methods highlight the breadth of
bacteria, and novel preparation methods and metagenomics address a shortcoming of conventional
next-generation sequencing, i.e. the amplification of sequences of nonviable bacteria [12–14]. Bacterial
abundance can be measured by quantitative PCR; however, 16S rRNA copy numbers per genome vary
between genera and quantitation of different genera in multispecies infections remains imprecise [15, 16].
Culture allows enumeration of the different bacterial genera in a polymicrobial infection, demonstrates
viability and growth in lower airways, and enables subsequent in vitro studies [17, 18]. Culturing anaerobic
and bacteria not typically considered as pathogenic is also relevant to clinical care, i.e. would knowledge
about abundance of these bacteria be useful for treatment?
Here, we assessed the association of strict anaerobes with disease severity in CF across all age ranges at
three CF centres with different genetic and geographic backgrounds and medications. Although “CF
pathogens” can grow under anaerobic conditions, this likely reflects adaptation to the microenvironment
and not distinct genera/infections. We used extended culture methods attempting to investigate the role
of anaerobes in CF lung disease. We focused on strict anaerobic bacteria to match genera reported in
molecular studies, and to ascertain the load and viability of these anaerobes in lower airways in relation
to typical CF pathogens. Three key questions were investigated. 1) Does the prevalence of anaerobes
versus aerobes in subjects with CF change as a function of age and site/climate? 2) Are there associations
between prevalence or quantity of anaerobes and genotype, disease severity and medications? 3) Are
community structures established by anaerobes and do they differ across ages, disease severity or
associations with aerobes?
Methods
Subjects and sample collection
People diagnosed with CF attending CF centres in Belfast in the UK (Adult and Paediatric CF Clinics,
Belfast Health and Social Care Trust), University of North Carolina (UNC) at Chapel Hill, NC in the USA
(UNC Hospital Pediatric and Adult Clinics) and Dublin in Ireland (Beaumont Hospital and Our Lady’s
Children’s Hospital, Crumlin) were prospectively enrolled into this study between July 2010 and
November 2013. Subjects who had undergone transplant, were taking CF transmembrane conductance
regulator potentiators/modulators or enrolled in interventional therapeutic trials were excluded. Ethical
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approval for the study was obtained at each institution, and informed consent/assent was obtained from all
adults, parents and paediatric subjects.
Either bronchoalveolar lavage (BAL) or sputum (if able to expectorate) and concomitant clinical
information were collected when subjects were clinically stable, defined as not having received antibiotics
beyond chronic maintenance therapy and ⩾6 weeks post-completion of intravenous antibiotic therapy.
Bronchoscopy was performed at UNC if a child had a procedure requiring anaesthesia and for routine
surveillance at Dublin. At both sites, bronchoscopy was performed utilising a laryngeal mask airway or
endotracheal tube.
Clinical data
Demographics, anthropometrics, lung function, medication history and disease complications were entered
into a centralised database. Genotype was categorised by number of F508del alleles. Disease severity was
assessed by nutritional status, pancreatic status and lung function (forced expiratory volume in 1 s (FEV1) %
pred; see supplementary material) if subjects were able to reliably perform spirometry as per American
Thoracic Society/European Respiratory Society criteria [19]. For comparisons of body mass index (BMI)
across paediatric and adult age ranges, BMI was stratified into poor, acceptable and well-nourished categories
based on percentiles in children (⩽5%ile, 6–50%ile and >50%ile) and absolute BMI in adults [20].
Bacterial isolation and identification
Standardised culture protocols were used across the three sites as previously described [6], with further
details provided in the supplementary material. Briefly, samples were treated for 15 min with dithiothreitol
prior to serial dilution and plating on both selective and nonselective media (supplementary table S1).
Plates were incubated under aerobic–micro-aerophilic and anaerobic conditions for between 2 and 7 days.
All bacteria detected were quantified (CFU·g−1 or CFU·mL−1 in BAL) by total viable count. Each distinct
colonial morphotype was identified by full-length 16S rRNA gene sequencing. Strict anaerobes were
defined as bacteria known not to survive under atmospheric oxygen tension, whereas facultative anaerobic
and aerobic bacteria that grew under anaerobic conditions were included as aerobes in all analyses.
Statistical analysis
Demographics, markers of disease severity and bacterial prevalence (presence of bacteria at any CFU >0)
were compared across clinical sites using the Chi-squared or Fisher’s exact test for categorical variables
and the Mantel–Haenszel mean score Chi-squared test for ordinal variables. Associations between
presence of bacteria and markers of disease severity were assessed by the Mantel–Haenszel mean score
Chi-squared test. Analyses were stratified by site as described.
Multivariate logistic regression was used to test for factors that predict prevalence of specific bacterial
genera. Predictors were identified via a stepwise model selection (with significance level for entry or
staying in the model of p=0.10 or p=0.05, respectively).
Analyses that included bacterial quantities/density were log-transformed to account for nonnormal
distributions using log10(CFU·g
−1+1) to incorporate samples with no detectable bacteria. Bacterial diversity
measures included richness (number of counted taxa), evenness and diversity (Shannon–Wiener index).
Analyses of bacterial communities (network analyses and factor analysis) were conducted on sputum
bacterial quantity for the most common genera. Co-occurrence (network analysis) between taxonomic
groups was calculated as previously described [21]. Factor analysis as an unsupervised method to group
genera was conducted using varimax rotations to achieve independent factor groupings. These factors were
used to assign each subject to a group defined by their dominating factor based on similarity of bacterial
quantities (see details in supplementary material).
Results
Subjects and samples
255 subjects were enrolled. Sputum samples (n=200) were obtained at all three sites, whereas BAL (n=55)
samples were collected only at UNC (n=24) and Dublin (n=31). All samples from children aged <6 years
were BAL (n=39). Either sputum (n=34) or BAL (n=12) were collected from subjects aged 6–<18 years;
for subjects aged ⩾18 years, 166 sputum and four BAL samples were collected.
Subject characteristics by site are shown in table 1. Site-specific differences in the study subjects included
older age and fewer subjects positive for F508del mutations in Belfast compared with UNC or Dublin.
Fewer subjects in Belfast were undernourished, and, despite being an older cohort, FEV1 values in Belfast
were similar to those in UNC and Dublin, consistent with milder disease in Belfast. Use of chronic
medications was lower in those contributing BAL versus sputum (supplementary table S2a and b).
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Prevalence and abundance of genera with age
18 anaerobic and 39 aerobic genera were cultured (supplementary table S3), representing 167 species
(supplementary table S4). The prevalence of one or more strict anaerobic genus at any CFU >0 in a
sample was 59% and was higher in sputum (67%) than BAL samples (31%) (p<0.001). Aerobic bacteria
were present at any CFU >0 in 197 out of 200 (99%) of sputum and in 51 out of 55 (93%) BAL samples.
The mean±SEM total viable counts were higher for aerobic than anaerobic bacteria in sputum
(2.27×108±3.80×107 versus 2.86×107±2.07×107 CFU·g−1; p<0.001) and BAL (3.97×107±3.71×107 versus
2.27×104±1.61×104 CFU·mL−1; p<0.001).
TABLE 1 Patient demographics by site
Overall Clinical site p-value#
Belfast Chapel Hill Dublin
Patients 255 75 65 115
Age years
Mean±SD 21.9±12.7 29.1±12.2 16.1±10.3 20.5±12.1
Median (range) 21.6 (1.0–68.2) 26.2 (8.3–68.2) 14.5 (1.0–50.0) 22.0 (1.0–61.2)
Age group years 255 75 65 115 <0.0001
0–<6 39 (15) 0 (0) 14 (22) 25 (22)
6–<13 21 (8) 4 (5) 13 (20) 4 (3)
13–<18 25 (10) 6 (8) 9 (14) 10 (9)
18–<25 77 (30) 22 (29) 18 (28) 37 (32)
25–<30 44 (17) 19 (25) 5 (8) 20 (17)
⩾30 49 (19) 24 (32) 6 (9) 19 (17)
Sex 255 75 65 115 0.13
Female 115 (45) 29 (39) 36 (55) 50 (43)
Male 140 (55) 46 (61) 29 (45) 65 (57)
F508del mutation 251 74 63 114 0.001
Homozygote 131 (52) 29 (39) 45 (71) 57 (50)
Heterozygote 99 (39) 34 (46) 15 (24) 50 (44)
None 21 (8) 11 (15) 3 (5) 7 (6)
Pancreatic status 255 75 65 115 0.61
Pancreatic sufficiency 223 (87) 64 (85) 59 (91) 100 (87)
Pancreatic insufficiency 32 (13) 11 (15) 6 (9) 15 (13)
BMI 235 74 65 96 0.01
Undernourished 26 (11) 3 (4) 9 (14) 14 (15)
Acceptable 118 (50) 34 (46) 37 (57) 47 (49)
Well nourished 91 (39) 37 (50) 19 (29) 35 (36)
FEV1 % pred¶ 212 74 51 87 0.02
<41 42 (20) 10 (14) 5 (10) 27 (31)
41–80 115 (54) 48 (65) 28 (55) 39 (45)
>80 55 (26) 16 (22) 18 (35) 21 (24)
Sample type 255 75 65 115 <0.0001
BAL 55 (22) 0 (0) 24 (37) 31 (27)
Sputum 200 (78) 75 (100) 41 (63) 84 (73)
Chronic antibiotics 173 (68) 58 (77) 43 (66) 72 (63) 0.10
Flucloxacillin 18 (7) 8 (11) 1 (2) 9 (8) 0.09
Azithromycin 127 (50) 44 (59) 37 (57) 46 (40) 0.02
Inhaled antibiotic+ 130 (52) 42 (56) 30 (47) 58 (52) 0.58
Any mucolytic 205 (80) 59 (79) 54 (83) 92 (80) 0.79
DNase 164 (64) 54 (72) 43 (66) 67 (58) 0.15
Hypertonic saline 109 (43) 15 (20) 37 (57) 57 (50) <0.0001
Inhaled corticosteroid 105 (41) 31 (41) 36 (55) 38 (33) 0.004
Antacid§ 129 (51) 32 (43) 41 (63) 56 (49) 0.05
Insulin 34 (13) 7 (9) 8 (12) 19 (17) 0.35
Data are presented as n or n (%), unless otherwise stated. BMI: body mass index; FEV1: forced expiratory
volume in 1 s; BAL: bronchoalveolar lavage. Patients were continuously enrolled at each site, not
necessarily reflecting the study site population. #: comparisons across sites using the Chi-squared,
Mantel–Haenszel mean score Chi-squared or Fisher’s exact test; ¶: based on Global Lung Initiative
reference values (see supplementary material); +: tobramycin, colistin and aztreonam; §: antacids,
H2-blockers and proton pump inhibitors.
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The ratio of anaerobic to aerobic viable counts for BAL and sputum showed no differences across age
groups (supplementary figure S1a). Bacterial richness was lower in BAL (3.03±0.31) compared with
sputum (5.18±0.16) (p<0.001), but similar within each sample type over age sextiles that approximate
clinical progression (figure 1a). Shannon diversities showed similar trends (supplementary figure S1b). 16
genera that had a ⩾5% prevalence across BAL and sputum samples are shown by age sextiles in




































































FIGURE 1 Changes in bacterial communities and prevalence with subject age: a) richness across age sextiles,
and b) prevalence of anaerobes, aerobes and specific genera across age sextiles. BAL: bronchoalveolar
lavage. a) Richness, defined as number of anaerobic and aerobic genera detected at any CFU >0 per sample,
did not differ between age groups within sample types (BAL and sputum). Boxes indicate the 25th–75th
quartiles with horizontal lines indicating the median; whiskers are 1.5 times the interquartile range.
b) Prevalence for the most prevalent bacteria shown by age group. The number of samples for each group is
given in parentheses. Bacterial density and prevalence were lower in BAL than sputum. Only BAL samples
are included in subjects aged <6 years.
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(51%) and Streptococcus (82%), respectively. More prevalent bacteria were more abundant with the
exception of Burkholderia with a 5% prevalence, but being most abundant when present, and Prevotella
with high prevalence, but low abundance. Changes in prevalence of the most frequently cultured anaerobes
and aerobes with age showed decreasing prevalence from childhood to mid-adulthood, with subsequent
increases for anaerobic genera and Streptococcus. Inverse trends were seen for Pseudomonas (figure 1b).
Analyses of samples by sites revealed differences in bacterial richness across sites, but similar diversity in
sputum samples (supplementary figure S2a). There were no differences in richness or diversity in BAL
samples from Dublin versus UNC (supplementary figure S2b). The prevalence of Pseudomonas was highest
at UNC, with Burkholderia, Haemophilus, Actinomyces, Rothia and Gemella being more prevalent in
Belfast. Neisseria prevalence was lowest in Belfast. Dublin had the lowest prevalence of Prevotella and
Veillonella. Further details are shown by site and sample type in supplementary table S3 and
supplementary figure S3.
Relationship between bacterial prevalence, abundance and disease severity
In subjects who produced sputum (n=200), anaerobes were associated with phenotypically milder disease,
e.g. better lung function and BMI, and with pancreatic sufficiency, absence of insulin and chronic
100a) b)
c) d)
* * * * * *
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FIGURE 2 Prevalence as percentage of subjects within the category with any CFU >0 for a) anaerobes, b) Haemophilus, c) Staphylococcus and
d) Pseudomonas in sputum and their association with clinical characteristics. BMI: body mass index; FEV1: forced expiratory volume in 1 s; PS:
pancreatic sufficiency; PI: pancreatic insufficiency; AZM: azithromycin. 200 sputum samples included. Seven subjects had missing data for FEV1
and eight subjects had missing data for BMI. BMI categories are 1: poor nutritional status; 2: adequate; 3: well nourished. FEV1 % pred categories
are 1: <40%; 2: 40–80%; 3: >80% (see supplementary material). Numbers per category are given as percentage of subjects positive for this
characteristic, where each category (e.g. “BMI 1”) can reach 100%. Inhaled antibiotics included tobramycin, colistin and aztreonam. *: significant
difference between groups by the Mantel–Haenszel mean score Chi-squared test stratified by site.
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antibiotic use, but not genotype (figure 2a). Haemophilus influenzae, an aerobe observed in early CF
disease, followed a similar pattern (figure 2b). Staphylococcus exhibited an intermediate pattern with
negative associations, i.e. was less prevalent, with use of chronic antibiotics (figure 2c). The pattern for
Pseudomonas, however, was distinctly different from anaerobes. Pseudomonas prevalence was positively
associated with worse BMI, number of F508del alleles and chronic antibiotics (figure 2d).
Logistic regression adjusting for covariates with p<0.05 identified through stepwise modelling revealed a
lower prevalence of anaerobes in pancreatic-insufficient subjects (table 2). With respect to aerobes, a lower
prevalence of Haemophilus and Staphylococcus was associated with use of azithromycin. Pseudomonas
prevalence again was associated with F508del alleles, and both azithromycin and inhaled antibiotic use.
For BAL, clinical or site variables were not associated with bacterial prevalence.
No associations were observed for absolute anaerobic or aerobic viable counts and clinical variables or
study site in sputum or BAL. However, calculation of the anaerobe/aerobe CFU ratio showed that subjects
with a relatively higher load of anaerobes had milder disease (pancreatic sufficiency and higher BMI) than
aerobe-dominated subjects (supplementary figure S4).
Community structure in sputum and association with subject characteristics
Bacterial communities reflecting the 16 genera with a ⩾5% prevalence were explored in sputum samples
(n=200) using microbial co-occurrence network analysis. Bacteria typical of the oropharynx, e.g.
Streptococcus, Rothia and Gemella, associated with each other. In contrast, Staphylococcus, Pseudomonas
and Burkholderia each formed distinct entities (figure 3).
Next, factor analysis was used to reduce the complexity of the microbiota per sample into a set of variables
that best defined sample community composition. The bacterial community compositions were generally
consistent with the co-occurrence networks. Five components/factors explained 49% of the variation
(figure 4). Factors 1 and 2 were dominated by oral-associated bacteria, including Streptococcus, Gemella
and Rothia. Factor 3 included Haemophilus and Neisseria. Factor 4 was dominated by obligate anaerobes.
Pseudomonas defined Factor 5, which was also negatively associated with Staphylococcus and Burkholderia.
To define the clinical relevance of these microbial communities, patient sputum samples were defined by
their dominating factor (table 3). Thus, each sample was assigned to Groups 1–5. There were no
differences in pancreatic status, use of azithromycin, mucolytics and anaerobic or aerobic bacterial load/
density between groups. Groups 4 and 5 had the highest percentage of F508del homozygous subjects, yet
differed significantly with regard to both anaerobes and Pseudomonas. The group with higher anaerobic
density/diversity (Group 4) tended to have a higher FEV1 and a lower incidence of poor nutritional status
compared with the Pseudomonas-dominated Group 5. Notably, Group 3 included the fewest subjects with
poor nutritional status and the most with a high FEV1, compared with other groups, but had the highest
proportion of subjects aged <20 years.
Discussion
Anaerobic and aerobic bacteria were cultured from respiratory samples across all age ranges to assess
bacterial prevalence and quantify density in CF respiratory secretions. The prevalence and quantities of both
TABLE 2 Odds ratios from logistic regression models of bacterial prevalence in sputum
Anaerobes Haemophilus Staphylococcus Pseudomonas
Patients n 197 197 200 195
F508del 1 versus 0 8.24 (1.00–68.20)
F508del 2 versus 0 17.63 (2.13–146.04)
Pancreatic insufficiency 0.12 (0.03–0.53)
Azithromycin 0.41 (0.18–0.92) 0.35 (0.19–0.62) 2.26 (1.10–4.67)
Inhaled antibiotic 0.26 (0.12–0.57) 3.97 (1.96–8.05)
Centre C versus B 0.58 (0.22–1.52)# 0.41 (0.15–1.08)#
Centre D versus B 0.17 (0.08–0.38) 0.17 (0.07–0.41)
Data are presented as OR (95% CI), unless otherwise stated. Variables evaluated for model inclusion were:
sex, age, centre (B: Belfast; C: Chapel Hill; D: Dublin), forced expiratory volume in 1 s and body mass index
as categories (as in figure 2), F508del, pancreatic status, chronic use of flucloxacillin, azithromycin, inhaled
antibiotics, DNase, hypertonic saline, corticosteroids, and antacids. Blank cells indicate these variables
were not selected for the final model because they were not significant predictors as determined by
stepwise model selection with p=0.10 for entry and p=0.05 for staying in the model. #: difference is not
significant but comparison included in model for comparison to centre D versus B.
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anaerobic and aerobic bacteria were lower in BAL compared with sputum. Interestingly, the anaerobe/aerobe
ratios in BAL, i.e. incorporating quantity, were similar to sputum. Facultative anaerobes and
micro-aerophilic bacteria were also cultured in both sample types (supplementary table S3) and were
included with aerobes, potentially underestimating the true anaerobic burden in the CF lung. Pseudomonas
and Staphylococcus also grow anaerobically, a growth mode associated with persistence in chronic infection,
but the focus in this study was on strict anaerobes as determined in molecular studies. The prevalence of
anaerobes and Streptococcus declined from early childhood to early adulthood, i.e. a time when many
patients experience worsening disease. In older age groups, anaerobes were more prevalent again, possibly
related to less severe disease (figure 1b) as reflected by the higher anaerobe/aerobe ratio in subjects with
better nutritional status (supplementary figure S4). Anaerobic and streptococcal species are highly abundant
in oral secretions, and are detected in the oral cavity in the first months of life [22]. Although oral secretions
are a source of contamination of sputum and BAL, the high abundance of anaerobic genera makes sample
contamination an unlikely explanation for our findings. Although BAL samples were obtained via a
laryngeal mask airway or endotracheal tube, which decreases the risk of contamination, the lower anaerobe
prevalence in BAL compared with sputum likely reflects the younger BAL subject age with lower bacterial
load and sample dilution. Aerobe prevalence and abundance were also lower in BAL than sputum. Typically,
BAL is assumed to represent a 30- to 80-fold dilution of epithelial lining fluid [23, 24].
The source of CF lower airways oral bacteria likely reflects micro-aspiration as reported in healthy subjects,
in whom oral bacteria are found in proximal airways but continuous mucociliary clearance prevents
growth to high densities [25, 26]. We suggest that starting in infancy, abnormal mucociliary clearance in
CF enhances retention of aspirated flora in an anaerobic airways environment, allowing anaerobic bacteria
to proliferate. Such a scenario is consistent with recent CF infant BAL microbiome analyses [27–29].
The contribution of anaerobic bacteria to lung disease is not clearly understood. This large study, which
analysed samples from 255 CF subjects across three sites and a wide age range, characterised the anaerobic
and aerobic microbial community composition in the CF airways using extended culture methods. A prior
molecular study had shown geographical differences in the CF microbiome [30]. In our study, differences
occurred by study site but not by continent, making climate a less relevant factor than genotype (e.g.

















FIGURE 3 Bacterial co-occurrence network between genera detected by extended microbial culture. The 16
genera detected at a ⩾5% prevalence from sputum samples are contained within the network. Co-occurring
microbial taxa are shown with nodes (circles) denoting a particular genus within the network and each edge
(blue lines) denoting a significant co-occurrence relationship (Spearman’s rank correlation coefficient) for
positive correlations lines); adjusted p-value <0.05 (Benjamini–Hochberg–Yekutieli false discovery rate
correction; see supplementary material). The size of the corresponding nodes demonstrates the relative
proportion of each genus within the current study and the thickness of the edges represents the strength of
the corresponding associations.
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sputum of subjects with milder disease. Higher lung function, increased BMI, pancreatic sufficiency and
absence of requirement for insulin were associated with higher prevalence of anaerobes in univariate
analyses (figure 2). Lower prevalence of anaerobes and Haemophilus in subjects on azithromycin could be
due to the antibacterial activity of azithromycin. Azithromycin exhibits good activity against those
organisms in non-CF disease; however, high rates of resistance are seen in CF that may mitigate its activity
[31, 32]. Notably, associations with pancreatic sufficiency remained significant when adjusting for multiple
medications and clinical parameters (table 2). A sensitivity analyses with p=0.1 for staying in the model
additionally included FEV1 for Pseudomonas, azithromycin and insulin for anaerobes, and hypertonic
saline for Haemophilus (supplementary table S6).
Our culture-based findings are consistent with observations from molecular microbiome studies describing
higher diversity with less severe CF lung disease [5, 33] and decreasing diversity in patients with more
rapid lung function decline [5, 11]. Our quantitative cultures allowed these relationships to be extended to
anaerobic and aerobic bacterial density, anaerobe/aerobe ratio and diversity. A higher anaerobe/aerobe
ratio was associated with pancreatic sufficiency and better nutrition, with trends for higher lung function
in those with a higher anaerobe/aerobe ratio (supplementary figure S4). However, associations between
absolute aerobic or anaerobic bacterial concentrations/density and FEV1 were not detected. We
hypothesise that the absence of such an association partly reflects the spatial heterogeneity of CF lung
disease, with bacterial density reflecting disease severity in focal bronchiectatic areas, whereas FEV1 reflects
the overall extent of diseased lung. The hypothesis that FEV1 is not sufficiently sensitive to detect regional,
bronchiectatic disease is supported by a study that reported associations between anaerobic density in CF
patients and lung clearance index, but not FEV1 [34]. Moreover, it should be noted that age-based
CF-specific lung function parameters developed for children [35] are not available for adults and effects of
genetic mutations on lung function were not included. Thus, although we used Global Lung Initiative
reference equations (see supplementary material) for comparison across body stature and centre, analyses
of relationships of bacterial density with FEV1 may have been more sensitive if CF- and age-specific
references were available.
Analyses of anaerobe pathogenicity in vitro may also yield insight into the relationships between anaerobes




















Factor 2 Factor 3 Factor 4 Factor 5
0.672 –0.056 0.166 –0.032 –0.076
0.574 0.274 0.087 0.109 –0.098
0.550 0.434 –0.162 0.121 0.004
0.496 –0.329 –0.123 –0.138 0.300
0.035 0.608 0.219 –0.095 0.150
–0.085 0.597 –0.282 0.122 –0.081
0.320 0.562 0.135 –0.094 –0.235
0.028 –0.075 0.736 –0.057 0.106
0.162 0.263 0.654 0.123 –0.166
–0.182 0.101 0.049 0.654 0.209
0.014 –0.201 –0.162 0.630 0.022
0.378 –0.027 0.352 0.557 –0.092
0.165 0.275 0.108 0.454 –0.236
–0.034 –0.097 –0.051 0.051 0.735
–0.245 –0.265 0.325 0.160 –0.491
0.179 0.039 –0.318 –0.097 –0.533
2.42 1.62 1.37 1.31 1.16
11.41 9.94 9.80 9.31 8.90
FIGURE 4 Loadings from factor analysis showing groupings of bacteria with each other based on quantity
in sputum (n=200 samples). Five factors explain 49% of the total variation. Blue indicates positive
associations and red indicates negative associations, with darker colours indicating the robustness of
associations.
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and has been reported consistently in other studies [5, 6, 10, 36–38]. In vitro studies of laboratory strains
of Prevotella demonstrated that they produce short-chain fatty acids and proteases that may be
pro-inflammatory [9]. However, Prevotella elicits diminished pro-inflammatory responses in respiratory
cell lines and murine models compared with classic aerobic pathogens [39]. Thus, conceivably the
relatively lower virulence of anaerobes contributes to their association with a milder CF phenotype.
Co-occurrence networks to visualise potential bacterial interactions showed groupings of orally derived
anaerobic bacteria, which occupied niches distinct from the known pathogens (e.g. Pseudomonas and
Staphylococcus) that were themselves highly dissimilar (figure 3). Both Burkholderia and Pseudomonas
release products that are toxic to other bacteria, which may contribute to their distinct niches as well as
their dominance [40]. CF registry data also demonstrate decreasing prevalence of Staphylococcus in older
patients as Pseudomonas prevalence increases, suggesting a similar community competition for these two
bacteria [41, 42].
Factor analyses (figure 4) revealed bacterial groupings similar to the co-occurrence networks. These
factors enabled testing of associations with clinical parameters based on samples defined by the highest
factor loadings (table 3). Group 4 with the highest prevalence and diversity of anaerobes had milder
disease than the Pseudomonas-dominated group, but not the mildest disease, possibly reflecting that
Group 4 exhibited the highest proportion of F508del homozygote subjects and moderate/high rates of
Pseudomonas.
A challenge to the present study is the inclusion of paediatric and adult age groups, necessitating
comparisons between BAL and sputum. For age-wide comparisons, prevalence was used as a surrogate
in addition to the ratio of anaerobic to aerobic bacterial load. Similar to prior studies, this study is
limited by its observational design and thus cannot determine the association versus causality with
respect to anaerobe-induced disease severity. This difference has an impact when considering targeted
anaerobe antibiotic therapy in subjects with CF. A recent study in infants with CF demonstrated more
airway inflammation in children whose airway microbiome was dominated by anaerobes compared
with “sterile” airways [29]. Anaerobes may also condition the lower CF airways to promote infection
with more classic pathogens [43]. Such data may support treatment of anaerobes in early CF disease.
In contrast, bacterial culture and molecular studies in older, sputum-producing subjects suggest that a
diverse lung microbiota with relatively abundant anaerobes is associated with milder disease.
Conceivably, higher anaerobic diversity in adults with milder disease reflects lower antibiotic use in
such subjects [44] and/or lower intrinsic virulence of anaerobes [39]. Therefore, targeted “eradication”
of anaerobes in older patients, when clinically at baseline, might result in little clinical benefit and
more resistant organisms. Anaerobes may increase at onset of exacerbations and therefore their role
may fluctuate with short-term changes in disease state [6, 14]. Anaerobes are not routinely cultured
for in the clinical setting. This approach may be justified in older subjects if antimicrobial therapy is
not being considered.
TABLE 3 Patient characteristics within the groups characterised by bacterial communities identified by factor analysis
Group 1 Group 2 Group 3 Group 4 Group 5 p-value#
Patients n 48 35 46 27 44
Age years 27.56±1.49 28.62±1.75 22.99±1.53 24.34±1.99 26.82±1.56 0.089
Age <20 years 27 17 43 37 20 0.048
Homozygote F508del 40 54 37 64 61 0.046
Null F508del 15 11 6 4 2 0.2
FEV1 % pred 59.47±3.17ƒ 55.79±3.78+ 75.64±3.28+,§,ƒ 61.58±4.26 57.08±3.35§ 0.0002
BMI kg·m−2 21.9±0.52 22.9±0.7 21.8±0.5 20.8±0.7 20.8±0.5 0.1
BMI category poor nutritional status 10 6 2 15 29 0.0033
Inhaled antibiotic use 67 66 35 56 78 0.0007
Pseudomonas-positive 38 37 39 59 91 <0.0001
Staphylococcus-positive 31 49 78 70 27 <0.0001
Any anaerobe 81 60 72 100 32 <0.0001
Aerobe richness 6.83±0.43+ 6.69±0.50§ 6.07±0.44 5.7±0.57¶ 4.57±0.45+,§ 0.0038
Anaerobe richness 1.75±1.19+ 1.20±0.23 1.59±0.20§ 3.22±0.26¶ 0.68±0.21+,§ <0.0001
Data are presented as mean±SD or %, unless otherwise stated. BMI: body mass index; FEV1: forced expiratory volume in 1 s. Groups 1 and 2
dominated by oral bacteria; Group 3 Haemophilus and Neisseria; Group 4 anaerobes; Group 5 Pseudomonas-dominated. Inhaled antibiotics included
tobramycin, colistin and aztreonam. #: p-values for comparison of categorical (Pearson) or continuous variables (ANOVA) across groups (p<0.05
considered significant). Adjusted difference (Tukey’s): ¶: differs from all other groups; +,§,ƒ: differences to corresponding symbol by row.
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In summary, anaerobic bacteria were detected in CF respiratory secretions at all ages. In the age groups
investigated in this study, aerobes dominated over anaerobes with respect to bacterial numbers. The
prevalence of anaerobic genera was associated with milder disease and lower use of antibiotics, suggesting
that a diverse anaerobic microbiota may be a marker of better health in older subjects with CF. Sputum
anaerobic/aerobic bacterial genera clustered into communities, which were associated with clinical
outcomes. Cross-sectional studies do not permit the distinction of anaerobes as markers versus causative
factors in the severity of lung disease. Collectively, our data suggest that targeted eradication of anaerobes
in the context of aerobic pathogenic bacteria may not be warranted until further data are available.
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